Mark Lewis and Bishal Gyawali
Aug 9, 2025, 21:21
Bishal Gyawali: This Has Always Been Our Bottom Line
Bishal Gyawali, Associate Professor at Queen’s University, shared a post on X about a recent paper by Laure-Anne Teuwen et al. published on JNCI:
“This has always been our bottom line.”
Title: Success in oncology phase 3 trials: a small P value or patient value
Authors: Laure-Anne Teuwen, Gregory R Pond, Bishal Gyawali
Mark Lewis, Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, shared Bishal Gyawali’s post:
” ‘A surrogate endpoint is something a patient didn’t know was important until a doctor said it was’ – Adam Cifu”
More posts featuring Bishal Gyawali and Mark Lewis.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 9, 2025, 21:22
Aug 9, 2025, 21:21
Aug 9, 2025, 19:54
Aug 9, 2025, 19:53
Aug 9, 2025, 19:37
Aug 9, 2025, 19:31
Aug 9, 2025, 19:17